Effects of intranasal administration of recombinant murine interferon-gamma on murine acute myocarditis caused by encephalomyocarditis virus

Circulation
N YamamotoM Kikuchi

Abstract

Viral myocarditis has been strongly implicated in the pathogenesis of dilated cardiomyopathy as well as acute myocarditis. Among the antiviral therapies, interferons (IFNs) have been widely studied and become very important in clinical practice. To investigate the possibilities of IFN therapy in viral myocarditis, we analyzed the effects of recombinant murine interferon (mIFN)-gamma and natural mIFN-alpha/beta by the intranasal and intramuscular routes on the development of acute murine myocarditis caused by encephalomyocarditis virus. Both mIFN-gamma and mIFN-alpha/beta treatment by either route significantly increased the survival rate; none of the mIFN-gamma-treated mice died. The effect of mIFN-gamma was significantly greater than that of mIFN-alpha/beta. Furthermore, intranasal administration of mIFN-gamma significantly suppressed virus replication and inflammation in the heart. Our data demonstrate that IFN therapy, especially intranasal administration of IFN-gamma, dramatically improved the prognosis of acute murine viral myocarditis by suppressing virus replication and raises the possibility of antiviral therapy with IFN-gamma in patients with acute myocarditis.

References

Feb 15, 1978·Biochemical Pharmacology·L S Schanker
Jan 1, 1985·Journal of Interferon Research·M R ShalabyB J Marafino
Jun 1, 1987·Journal of the American College of Cardiology·A MatsumoriW H Abelmann
Oct 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·B Y Rubin, S L Gupta
Jul 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·R KamijoJ Vilcek
Dec 1, 1995·European Heart Journal·M Stille-SiegenerH R Figulla

❮ Previous
Next ❯

Citations

Jan 29, 2008·Current Treatment Options in Cardiovascular Medicine·William H FrishmanNauman Naseer
May 25, 2002·Heart Disease·William H FrishmanSharmila Anandasabapathy
Sep 4, 2009·Future Virology·Scott ParkerR Mark Buller
Apr 17, 2013·Heart Failure Reviews·Scott P Levick, Paul H Goldspink
Dec 13, 2000·Journal of Molecular and Cellular Cardiology·T KandaI Kobayashi
Dec 5, 2008·Expert Review of Vaccines·Andreas HenkePeter Wutzler
May 23, 2013·Annals of the New York Academy of Sciences·Jobert G Barin, Daniela Čiháková
Aug 18, 2005·Cytokine·Hongkui JinNicholas F Paoni
Oct 17, 2014·Journal of Virology·Mary K McCarthyJason B Weinberg
Jun 11, 2020·Biomolecules·Morgana K B PradoLúcia H Faccioli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.